Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial
Rakesh Popat, Bradley Augustson, Paul Cannell, et al.
Cancer
|
March 30, 2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Thomas G Martin, Maria Victoria Mateos, Ajay Nooka, et al.
British Journal of Haematology
|
April 15, 2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data
Noa Biran, Binod Dhakal, Ruben Niesvizky, et al.
Blood Cancer Journal
|
June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Blood Cancer Journal
|
September 4, 2021
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Karthik Ramasamy, Ajay Nooka, Hang Quach, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
The Lancet. Haematology
|
February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Michel Delforge, Krina Patel, Laurie Eliason, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 13, 2018
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Kathleen M Mullane, Drew J Winston, Ajay Nooka, et al.
JCI Insight
|
May 20, 2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Noffar Bar, Federica Costa, Rituparna Das, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study
Sagar Lonial, Jonathan Kaufman, Mourad Tighiouart, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 2, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: the DREAMM-6 Arm B Trial
Rakesh Popat, Bradley Augustson, Paul Cannell, et al.
Cancer
|
March 30, 2023
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
Thomas G Martin, Maria Victoria Mateos, Ajay Nooka, et al.
British Journal of Haematology
|
April 15, 2025
Enhancing risk stratification and treatment decision in multiple myeloma with SKY92 gene expression profiling in real-world data
Noa Biran, Binod Dhakal, Ruben Niesvizky, et al.
Blood Cancer Journal
|
June 19, 2021
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, et al.
Blood Cancer Journal
|
September 4, 2021
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma
Karthik Ramasamy, Ajay Nooka, Hang Quach, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
The Lancet. Haematology
|
February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Michel Delforge, Krina Patel, Laurie Eliason, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 13, 2018
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Kathleen M Mullane, Drew J Winston, Ajay Nooka, et al.
JCI Insight
|
May 20, 2020
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Noffar Bar, Federica Costa, Rituparna Das, et al.
Page
of 5